Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase 2 Terminated 17 enrolled New Mexico Cancer Research Alliance

NaSingle-groupOpen-labelTreatment

Summary

1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dose administration of chemotherapy on angiogenesis, and correlate this with tumor responses.

Timeline

Start: 2004-10
Primary completion: 2008-11
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	200 mg	Intravenous
Subject	Etoposide	Small molecule	50 mg	Oral
Subject	Vincristine	Small molecule	2 mg	Intravenous
Background	Levofloxacin	Small molecule	500 mg	Oral
Background	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Summary

Timeline

Drugs

Indications